BARDA Backs Arcturus' Influenza Vaccine Program

  • Arcturus Therapeutics Holdings Inc ARCT received an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA). 
  • The award provides three years to support preclinical, manufacturing, and nonclinical safety studies, along with development and regulatory support for Arcturus' self-amplifying mRNA vaccine platform technology for rapid pandemic influenza response through Phase 1 studies.
  • Also see: Arcturus' COVID-19 Booster Shows Durability Against Omicron Variants.
  • The company says its self-amplifying mRNA vaccine has been administered to over 10,000 individuals globally, demonstrating favorable safety, strong immunogenicity, and protection against SARS-COV-2 infection.
  • Price Action: ARCT shares are down 2.68% at $13.66 on the last check Thursday.

Posted In: BiotechGovernmentHealth CareSmall CapGeneralBriefs